Curcumin is a natural bioactive compound derived from the rhizome of turmeric (Curcuma longa L.), best known for its intense yellow-orange color. It is responsible for most of turmeric’s biological properties. From a chemical perspective, curcumin belongs to the group of polyphenols—plant-derived compounds that have been extensively studied for their effects on inflammatory processes and oxidative stress in the body.
Scientific studies indicate that curcumin exhibits anti-inflammatory and antioxidant properties and may also regulate glucose and lipid metabolism. These effects are particularly relevant in the context of metabolic disorders, in which chronic inflammation and oxidative stress play a key role. One such condition is metabolic dysfunction–associated steatotic liver disease (MASLD), defined as hepatic steatosis occurring alongside at least one metabolic abnormality, such as overweight, obesity, or type 2 diabetes mellitus (T2DM). This condition is highly prevalent among individuals with T2DM and is associated with chronic inflammation, oxidative stress, and progressive liver fibrosis.
The significance of curcumin in this context was confirmed by a randomized, double-blind, placebo-controlled clinical trial published in 2025. The study included 78 adult participants diagnosed with T2DM and MASLD. Participants were randomly assigned to receive either curcumin at a daily dose of 1500 mg or a placebo. Clinical and biochemical parameters were assessed at baseline and at 3, 6, 9, and 12 months of supplementation, allowing evaluation of both short- and long-term effects. Throughout the study, metabolic parameters, inflammatory markers, and liver status were regularly monitored.
The results were promising. Participants receiving curcumin supplementation demonstrated a significant reduction in substances that sustain chronic inflammation, including pro-inflammatory cytokines TNF-α, IL-1β, and IL-6. At the same time, levels of oxidative stress markers decreased, which is relevant given their role in the progression of fatty liver disease.
Importantly, improvements were not limited to laboratory parameters alone. Imaging assessments revealed reduced liver fat accumulation and improved liver elasticity, suggesting a beneficial effect of curcumin on liver structure and function. A decrease in circulating free fatty acids was also observed, which is known to promote hepatic fat accumulation and exacerbate metabolic dysfunction.
An additional observed effect was improved glycemic control. Participants receiving curcumin showed reductions in fasting blood glucose levels and glycated hemoglobin (HbA1c), independent of body weight loss. Concurrently, reductions in waist circumference and total body fat were observed, indicating a favorable impact on selected metabolic risk factors.
Equally important, the supplementation was well tolerated, and no serious adverse events were reported by the study authors, confirming the safety of curcumin even with long-term use.
The collected scientific evidence indicates that curcumin is a raw material with well-documented biological activity and a broad potential for application. Its anti-inflammatory and antioxidant properties, supported by both clinical trials and meta-analyses, make it a valuable ingredient for dietary supplements and nutraceutical products.
Prepared based on:
Yaikwawong, M.; Jansarikit, L.; Jirawatnotai, S.; Chuengsamarn, S. Curcumin for Inflammation Control in Individuals with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial. Nutrients 2025, 17, 1972. https://doi.org/10.3390/nu17121972
